RedHill Biopharma Ltd. (RDHL)
1.39
+0.03
(+2.21%)
USD |
NASDAQ |
Jan 20, 14:29
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.629M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -76.11% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.99% |
Profile
| RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel. |
| URL | http://www.redhillbio.com |
| Investor Relations URL | https://ir.redhillbio.com/ |
| HQ State/Province | Tel Aviv |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Apr. 25, 2017 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel. |
| URL | http://www.redhillbio.com |
| Investor Relations URL | https://ir.redhillbio.com/ |
| HQ State/Province | Tel Aviv |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Apr. 25, 2017 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |